Literature DB >> 27065574

Von Willebrand Disease Lab Diagnosis.

Francine Charan de Faria1, Railson Henneberg2, Aguinaldo José do Nascimento2, Karen Sumire Kubo3, Henrique Ravanhol Frigeri3, Paulo Henrique da Silva2.   

Abstract

The hemorrhagic diseases are characterized by bleeding which can vary considerably according to their severity. The von Willebrand disease (VWD) is the most frequent hereditary hemorrhagic disease and the prevalence of clinically significant disease is probably closer to 1:1000, being an extremely heterogeneous and complex disorder that is related to the deficiency in concentration, structure or function of von Willebrand factor (VWF). The VWD is divided into type 1, with partial deficiency of the VWF, type 2, with qualitative defects in the molecule with four subdivisions, and type 3, with very low or undetectable levels of plasma and platelet VWF and ristocetin cofactor activity. The laboratory diagnosis of VWD is complex. Specific tests that assess the functionality and concentrations of the VWF and FVIII are needed. The routine tests are the bleeding time, the activated partial thromboplastin time and the platelet count, however, singly, they may not suggest the diagnosis of VWD, requiring further specific tests, such as VWF function evaluation through its ristocetin cofactor assay (VWF:RCo), VWF protein concentration immunoassay (VWF:Ag), the factor VIII coagulation assay ( FVIII: C), VWF binding to immobilized collagen (VWF:CB), ristocetin-induced platelet aggregation (RIPA), VWF multimers patterns, factor VIII binding of immobilized VWF (VWF:FVIIIB), among others. From the moment the diagnosis is confirmed, the appropriate treatment for each patient is sought, with the purpose of increasing plasma concentrations of the deficient protein, both in bleeding episodes, as for invasive procedures. Although diagnosis facilitates treatment other approach in the present scenario is prenatal diagnosis which, is the need of the hour.

Entities:  

Keywords:  Platelet aggregation; Platelet count; Ristocetin cofactor; Von Willebrand disease; Von Willebrand factor

Year:  2015        PMID: 27065574      PMCID: PMC4789000          DOI: 10.1007/s12288-015-0627-x

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  9 in total

Review 1.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

Review 2.  An update on type 2B von Willebrand disease.

Authors:  Sameh Mikhail; Ehab Saad Aldin; Michael Streiff; Amer Zeidan
Journal:  Expert Rev Hematol       Date:  2014-02-12       Impact factor: 2.929

3.  [Platelet aggregation test: application in the control of antiplatelet aggregation in the secondary prevention of stroke].

Authors:  Patrícia Regina Piedade; Rubens José Gagliardi; Ibsen Thadeo Damiani; Antonio Paulo Nassar Junior; Melissa Martins Fuzaro; Wilson Luiz Sanvito
Journal:  Arq Neuropsiquiatr       Date:  2003-10-28       Impact factor: 1.420

4.  Determination of normal range of bleeding time in rural and urban residents of Borujerd, Iran: A pilot study.

Authors:  Ali Maleki; Hamidreza Roohafza; Negin Rashidi; Farshid Aliyari; Reza Ghanavati; Saeed Foroughi; Behjat Nabatchi; Maria Torkashvand
Journal:  ARYA Atheroscler       Date:  2012

5.  [Anesthesia for septoplasty and turbinectomy in von Willebrand disease patient: case report].

Authors:  Múcio Paranhos de Abreu; André de Moraes Porto; Alexandre Leite Minari; Henrique Gonçalves Caseli
Journal:  Rev Bras Anestesiol       Date:  2003-06       Impact factor: 0.964

6.  [Von Willebrand factor and pulmonary endothelial dysfunction. Prognostic implications].

Authors:  A A Lopes; N Y Maeda; S P Bydlowski
Journal:  Arq Bras Cardiol       Date:  1998-03       Impact factor: 2.000

7.  [Von Willebrand's disease and anesthesia.].

Authors:  Fabiano Timbó Barbosa; Rafael Martins da Cunha; Luciano Timbó Barbosa
Journal:  Rev Bras Anestesiol       Date:  2007-06       Impact factor: 0.964

8.  The Prevalence of von Willebrand Disease and Significance of in Vitro Bleeding Time (PFA-100) in von Willebrand Disease Screening in the İzmir Region.

Authors:  Fatih Sap; Tülay Kavaklı; Kaan Kavaklı; Ceyhun Dizdarer
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

Review 9.  Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.

Authors:  Marcus Stockschlaeder; Reinhard Schneppenheim; Ulrich Budde
Journal:  Blood Coagul Fibrinolysis       Date:  2014-04       Impact factor: 1.276

  9 in total
  1 in total

1.  Increased von Willebrand factor parameters in children with febrile seizures.

Authors:  Astrid Pechmann; Sven Wellmann; Benjamin Stoecklin; Marcus Krüger; Barbara Zieger
Journal:  PLoS One       Date:  2019-01-03       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.